Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) is a clinical-stage biotechnology company developing immunotherapies that target the CD40 ligand (CD40L) pathway. Its lead candidate, tegoprubart, is an antibody designed to block CD40L signaling. The company’s main focus is preventing rejection in kidney transplantation,… From the company’s description.
In fiscal 2025, Eledon Pharmaceuticals, Inc. reported a net loss of $45.62M. Operations used $62.34M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Eledon Pharmaceuticals, Inc. does
In the company’s own words
Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) is a clinical-stage biotechnology company developing immunotherapies that target the CD40 ligand (CD40L) pathway. Its lead candidate, tegoprubart, is an antibody designed to block CD40L signaling. The company’s main focus is preventing rejection in kidney transplantation, where it is evaluating tegoprubart as an alternative to calcineurin inhibitor-based immunosuppression. It is also pursuing research collaborations involving xenotransplantation, in which organs from animals are transplanted into people, and supports an investigator-initiated islet-cell transplantation study. Tegoprubart has also been studied for amyotrophic lateral sclerosis (ALS); further development in that indication depends on additional financing. Eledon has no reportable business segments described and centers its development activities on tegoprubart. The company acquired Anelixis Therapeutics in 2020, gaining the intellectual property related to the antibody, and subsequently ended its legacy ear, nose and throat programs. Its website is www.eledon.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- IRVINE, CA
- Fiscal year end
- December
- CIK
- 1404281
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Eledon Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Eledon Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Eledon Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Eledon Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Eledon Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”